Skip to main content
OpenTrials
Completed

NCT Number: NCT03046589

DP13 SAD & MAD in Healthy Male Subjects

Primary Objectives:

1. To determine the safety and tolerability of single and multiple oral doses of DP13 in healthy male subjects 2. To assess the pharmacodynamics of single and multiple ascending oral doses as well as dosing regimen of DP13 on suppression of serum aldosterone in healthy male subjects

Secondary Objectives:

1. To determine the single and multiple oral dose pharmacokinetics of DP13 in healthy male subjects 2. To determine the dose-dependent pharmacodynamic selectivity of DP13 in healthy male subjects

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Covance Clinical Research Unit Ltd

Leeds, LS2 9LH, United Kingdom

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • BMI between 18.0 and 30.0 kg/m2, inclusive
  • body weight between 60 and 95 kg, inclusive
  • good health as determined by medical history, physical examination, vital signs assessment, 12-lead ECG, clinical laboratory evaluations
  • normal stress response
  • sodium value within the normal laboratory reference range
  • potassium value within the normal laboratory reference range
  • written informed consent

Exclusion criteria

  • unwilling to consent or whose partner is unwilling to consent to use a barrier method of contraception
  • blood donation within 3 months prior to screening or plasma donation within 7 days prior to screening or platelet donation within 6 weeks prior to screening
  • consumption of more than 28 units of alcohol per week or significant history of alcoholism or drug/chemical abuse within the last 12 months prior to screening
  • use of tobacco or nicotine-containing products within 3 months
  • use of any of the following within 14 days of first dose: non-prescribed systemic or topical medication; any herbal remedy; any vitamin supplement; any mineral supplement
  • receipt of any medications, including St John's Wort, known to chronically alter drug absorption or elimination processes
  • receipt or intent to receive: any prescribed systemic or topical medication within 14 days of first dose administration
  • an abnormality in heart rate, blood pressure, temperature or respiration rate at screening and prior to first dose that in the opinion of the investigator increases the risk of participating in the study
  • a positive urine drugs of abuse screen
  • an abnormality in the 12-lead ECG at screening and prior to first dose that in the opinion of the investigator increases the risk of participating in the study
  • a medical history of clinically significant ECG abnormalities or a family history of a prolonged QT-interval syndrome
  • participation in another clinical study

Treatment and study plan

DP13

Drug

dose escalation

Placebo

Drug

control to dose-escalation

Primary outcomes

  1. Safety and Tolerability (Clinical signs and symptoms incl ECG, vital signs, electrolytes)

    Time frame: Up to 2 weeks after dosing

    Clinical signs and symptoms incl ECG, vital signs, electrolytes

  2. Aldosterone suppression

    Time frame: Up to 48 hours after dosing

    Serum aldosterone concentration

Secondary outcomes

  1. Pharmacokinetics (Plasma DP13 concentration)

    Time frame: up to 48 hours after dosing

    Plasma DP13 concentration

  2. Pharmacodynamic selectivity (Plasma hormone concentrations)

    Time frame: Up to 48 hours after dosing

    Plasma hormone concentrations

Sponsors and collaborators

Lead sponsor

Damian Pharma AG

Industry

Collaborators

  • Covance
  • Foundation for Therapeutic Research, Lausanne
  • Insel Gruppe AG, University Hospital Bern

Registry information

Official study title

A Phase 1, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Oral Dose, Safety, Tolerability, Pharmacodynamic, and Pharmacokinetic Study of DP13 in Healthy Male Subjects

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Feb 8, 2017
Registry last updated
Apr 17, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.